Overview
At a Glance
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic peptide that stimulates growth hormone release through the ghrelin receptor. It's notable for causing significant hunger spikes — a ghrelin-like side effect that distinguishes it from other GH secretagogues. It has research applications in studying GH physiology but limited clinical utility due to its side-effect profile. It is not FDA-approved and is sold as a research chemical.
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone (GH) release from the anterior pituitary gland through activation of the ghrelin receptor (GHS-R1a). It was one of the earliest growth hormone secretagogues developed and has served as a foundational research tool for understanding ghrelin receptor biology and GH regulation (Bowers et al., 1998).
GHRP-6 was developed through systematic modification of met-enkephalin peptide analogs in the 1980s. Cyril Bowers and colleagues at Tulane University discovered that certain enkephalin derivatives had unexpected GH-releasing activity unrelated to opioid receptor pathways. GHRP-6 emerged as one of the most potent early compounds in this series, predating the discovery of ghrelin itself. In fact, the development of GHRPs ultimately led to the identification of the endogenous ghrelin receptor and its natural ligand, ghrelin (Bowers, 2001).
GHRP-6 is distinguished from other GH secretagogues by its pronounced appetite-stimulating effect. Among the GHRP family, GHRP-6 produces the strongest hunger response — a direct consequence of its potent ghrelin receptor activation in hypothalamic appetite-regulating centers. It also elevates cortisol and prolactin, making it less selective than newer secretagogues such as Ipamorelin (Arvat et al., 2001).
GHRP-6 is not approved for therapeutic use by the FDA, EMA, or any other major regulatory authority. It has been studied in Phase 1–2 clinical trials and is available as a research chemical. It is prohibited by WADA in competitive sport.
Quick Facts
| Property | Details |
|---|---|
| Molecular formula | C₄₆H₅₆N₁₂O₆ |
| Amino acid sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular weight | ~873.01 Da |
| Receptor target | Growth hormone secretagogue receptor (GHS-R1a) |
| Routes studied | Subcutaneous injection, intravenous, intranasal |
| Human trials | Phase 1–2 completed |
| FDA approval | None |
| WADA status | Prohibited (S2 — Peptide Hormones, Growth Factors) |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
GHRP-6 acts through the same primary receptor as other GH secretagogues — the growth hormone secretagogue receptor type 1a (GHS-R1a). This G protein-coupled receptor is expressed in the hypothalamic arcuate nucleus, the anterior pituitary somatotroph cells, and various peripheral tissues including the heart, adipose tissue, and GI tract (Muccioli et al., 2007).
GHS-R1a Receptor Activation and GH Release
When GHRP-6 binds to GHS-R1a, it triggers phospholipase C activation, inositol triphosphate (IP3) production, and intracellular calcium mobilization in pituitary somatotrophs, resulting in GH vesicle exocytosis. At the hypothalamic level, GHRP-6 stimulates GHRH-producing neurons and suppresses somatostatin tone, both of which contribute to enhanced GH release (Bowers et al., 1998).
Appetite Stimulation
GHRP-6's appetite-stimulating effect is its most distinguishing pharmacological feature. This occurs through:
- Hypothalamic NPY/AgRP activation: GHS-R1a activation in the arcuate nucleus stimulates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons — the primary orexigenic (appetite-promoting) neurons in the hypothalamus. GHRP-6 produces a more robust activation of these pathways than GHRP-2 or Ipamorelin (Muccioli et al., 2007).
- Vagal afferent signaling: GHS-R1a is expressed on vagal nerve afferents in the GI tract. GHRP-6 activation of these receptors sends hunger signals to the brainstem nucleus of the solitary tract (NTS), contributing to appetite drive.
- Gastric motility: GHRP-6 promotes gastric emptying and GI motility through peripheral GHS-R1a activation, which further stimulates appetite through mechanical and chemical satiety signal modulation.
Synergy with GHRH
Like GHRP-2, GHRP-6 produces synergistic GH release when co-administered with GHRH or GHRH analogs. The two receptor systems (GHS-R1a and GHRH-R) activate complementary intracellular signaling cascades (PLC/calcium vs. cAMP/PKA), and their convergence on GH vesicle release produces an amplified response. Combined GHRP-6 + GHRH produces GH peaks 3–5 times greater than either agent alone (Bowers et al., 1998).
Cortisol and Prolactin Effects
GHRP-6, like GHRP-2, stimulates cortisol and prolactin release:
- Cortisol: GHRP-6 activates the hypothalamic-pituitary-adrenal (HPA) axis, producing transient ACTH and cortisol elevation. This effect is dose-dependent and comparable in magnitude to GHRP-2 (Arvat et al., 2001).
- Prolactin: Modest, transient prolactin elevation occurs, similar to GHRP-2. The mechanism may involve hypothalamic dopamine pathway modulation (Arvat et al., 2001).
IGF-1 Pathway
GH released in response to GHRP-6 stimulates hepatic IGF-1 production. IGF-1 mediates many of GH's downstream anabolic effects, including protein synthesis, cell proliferation, and tissue repair. Chronic GHRP-6 administration leads to sustained IGF-1 elevation, which serves as a biomarker for GH axis stimulation (Bowers, 2001).
Cardioprotective Effects
Independent of GH release, GHRP-6 has demonstrated direct cardioprotective effects in preclinical models. GHS-R1a is expressed in cardiac tissue, and GHRP-6 activation of this receptor reduces apoptosis, oxidative stress, and inflammatory cytokine production in ischemia-reperfusion injury models. These effects have been documented in multiple animal studies and are distinct from the cardioprotective effects of GH/IGF-1 themselves (Muccioli et al., 2007).
Go Deeper
- Bowers et al. (1998) — "GH secretagogue development from GHRP-6 to ghrelin" — PubMed
- Muccioli et al. (2007) — "Ghrelin receptor biology and appetite regulation" — PubMed
- Arvat et al. (2001) — "Endocrine activities of GHRP-6 in humans" — PubMed
- Muccioli et al. (2007) — "Cardiac GHS-R1a and cardioprotection" — PubMed
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Research
GH Stimulation Studies
- Dose-response in humans: Intravenous and subcutaneous GHRP-6 produce dose-dependent GH peaks in healthy volunteers. At 1 mcg/kg IV, significant GH elevations are observed within 15–30 minutes, with return to baseline by 2–3 hours. The GH response is comparable to but slightly less potent than GHRP-2 on a per-microgram basis (Bowers et al., 1998).
- Elderly subjects: GHRP-6 retains GH-stimulating activity in elderly subjects with age-related GH decline, though the response is attenuated compared to younger adults (Bowers, 2001).
- Obese subjects: GH response to GHRP-6 is blunted in obesity, consistent with the known suppressive effect of elevated free fatty acids and insulin on GH secretion (Arvat et al., 2001).
- GHRH synergy: Combined GHRP-6 + GHRH administration produces synergistic GH release, as documented in multiple controlled human studies (Bowers et al., 1998).
Cardioprotection
Cardioprotection is one of the most extensively studied applications of GHRP-6 in preclinical models:
- Myocardial ischemia-reperfusion: GHRP-6 reduced infarct size by 40–50% in rat and pig models of myocardial ischemia-reperfusion injury. The protective effect was mediated through GHS-R1a-dependent reduction of oxidative stress, inflammatory cytokines, and cardiomyocyte apoptosis (Muccioli et al., 2007).
- Cardiac fibrosis: GHRP-6 reduced myocardial fibrosis in chronic heart failure models, preserving ventricular function and reducing collagen deposition (Berlanga et al., 2007).
- Mechanism: The cardioprotective effects appear to be mediated through activation of the PI3K/Akt survival pathway and suppression of NF-κB inflammatory signaling, independent of GH release (Muccioli et al., 2007).
Wound Healing
- Diabetic wound models: GHRP-6 accelerated wound closure in diabetic rat models, with enhanced granulation tissue formation, angiogenesis, and collagen deposition at the wound site. These effects are relevant given the clinical challenge of impaired wound healing in diabetic patients (Berlanga et al., 2007).
- Burn wound healing: Topical and systemic GHRP-6 improved burn wound healing in animal models, with accelerated re-epithelialization and reduced inflammatory infiltrate (Berlanga et al., 2007).
Gastroprotection
- Gastric mucosal protection: GHRP-6, through its ghrelin-mimetic activity, has demonstrated gastroprotective effects in animal models of gastric ulceration. Ghrelin receptor activation in the GI tract promotes mucosal blood flow, mucus secretion, and epithelial cell survival (Muccioli et al., 2007).
Appetite and Metabolism
- Food intake studies: GHRP-6 increases food intake in both animal models and human studies. In humans, subjective hunger ratings increase significantly within 20–30 minutes of administration (Arvat et al., 2001).
- Cachexia models: GHRP-6's appetite-stimulating properties have been investigated for potential application in cachexia (wasting syndrome) associated with cancer, HIV/AIDS, and chronic illness. Preclinical data suggests improved food intake and body weight preservation (Muccioli et al., 2007).
Comparison with Other GH Secretagogues
| Compound | GH Potency | Appetite | Cortisol | Prolactin | Selectivity |
|---|---|---|---|---|---|
| GHRP-6 | Moderate-high | Strong | Moderate | Mild-moderate | Low |
| GHRP-2 | High | Moderate | Moderate | Mild-moderate | Low-moderate |
| Ipamorelin | Moderate | Minimal | Minimal | Minimal | High |
| Hexarelin | High | Moderate | Moderate-high | Moderate | Low |
Limitations of the Research
- No Phase 3 trials: Despite Phase 1–2 human data, no large-scale efficacy trials for any therapeutic indication have been completed.
- Cardioprotection data is preclinical: The cardioprotective findings, while robust in animal models, have not been translated to human clinical trials.
- Short-term human studies: Most human pharmacodynamic data comes from acute or short-term studies. Long-term safety and efficacy data is absent.
- Appetite as limitation: The pronounced appetite stimulation, while potentially beneficial for cachexia, is a limitation for individuals using GHRP-6 for body composition or anti-aging purposes.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
FDA Status
GHRP-6 has no FDA-approved indication. It has not been approved for therapeutic use by the FDA, EMA, MHRA, TGA, or any other major regulatory authority. It has not completed Phase 3 clinical trials for any indication. Any use is considered experimental.
Off-Label and Research Applications
| Application | Evidence Basis | Notes |
|---|---|---|
| GH optimization / anti-aging | Phase 1–2 human data | Used to stimulate endogenous GH production. Less commonly chosen than GHRP-2 or Ipamorelin due to strong appetite stimulation. |
| Appetite stimulation (cachexia) | Preclinical + Phase 1 human data | The pronounced appetite effect makes GHRP-6 of particular interest for wasting syndromes associated with cancer, HIV/AIDS, or chronic illness. |
| Body composition | Limited human data | Used for GH-mediated fat loss and lean mass support, though the appetite effect can counteract caloric deficit goals. |
| Injury recovery | Indirect (GH/IGF-1 mediated) | GH and IGF-1 support tissue repair. GHRP-6 used as an adjunct to elevate these factors during recovery. |
| Wound healing | Preclinical | Based on animal models showing accelerated wound closure, particularly in diabetic wound models. Not validated in human trials. |
| Sleep optimization | Preliminary | Pre-sleep administration to enhance nocturnal GH pulse. Appetite stimulation at bedtime is reported as a drawback. |
What GHRP-6 Is NOT Used For
- Direct muscle building: GHRP-6 is not an anabolic steroid and does not directly increase testosterone or produce androgenic effects.
- Weight loss: GHRP-6's strong appetite stimulation makes it a poor choice for weight loss protocols. The hunger effect can lead to increased caloric intake that offsets GH-mediated lipolysis.
- Cardioprotective therapy in humans: While preclinical cardioprotection data is promising, GHRP-6 has not been evaluated for cardiac indications in human trials.
- Replacement for standard GH therapy: GHRP-6 is not a substitute for approved GH replacement in patients with documented GH deficiency.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
GHRP-6 is not FDA-approved for any indication. No official therapeutic dosing guidelines exist. The information below reflects protocols commonly reported in clinical practice and research literature — it is provided for informational purposes only. Do not self-administer any peptide without guidance from a qualified healthcare provider. Dosing, preparation, and administration should be overseen by a licensed clinician.
Commonly Reported Protocols
| Protocol | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Standard GH stimulation | 100–300 mcg SC | 2–3x daily | Administered on an empty stomach. Expect significant appetite stimulation within 20–30 minutes. Timed around natural GH pulse windows: morning, post-workout, before sleep. |
| Conservative / entry | 100 mcg SC | 1–2x daily | Lower dose to assess tolerance and minimize appetite/cortisol effects. |
| Combined with GHRH analog | 100–200 mcg GHRP-6 + 100 mcg mod GRF 1-29 | 2–3x daily | Synergistic protocol. Greater GH release than either agent alone. |
| Appetite stimulation (cachexia) | 200–300 mcg SC | 2–3x daily, pre-meal | Timed 20–30 minutes before meals to maximize appetite-stimulating effect. |
Sources: Bowers et al. (1998) — dose-response in humans; Arvat et al. (2001) — endocrine dose-response.
Timing Considerations
- Fasting state: GH release in response to GHRP-6 is significantly blunted by elevated blood glucose and insulin. Administration on an empty stomach (minimum 1–2 hours post-meal) is considered important.
- Appetite management: The intense appetite stimulation occurs within 20–30 minutes of administration and typically lasts 30–60 minutes. Some users time doses before planned meals to align the hunger response with eating.
- Pre-sleep considerations: The pre-sleep dose enhances the nocturnal GH surge but may cause disruptive hunger that interferes with sleep onset for some individuals.
- Spacing: Doses separated by at least 3 hours to maintain pulsatile GH release pattern.
Dose and Side Effect Relationship
- 100 mcg: Moderate GH stimulation with noticeable but manageable appetite increase. Mild cortisol effect.
- 200 mcg: Stronger GH peak with pronounced appetite stimulation and moderate cortisol elevation.
- 300 mcg: Near-maximal GH response with strong appetite drive and clinically significant cortisol increase. GH response plateaus above this dose.
- >300 mcg: Diminishing GH returns with increasing side effect burden. Generally not recommended.
Cycling Patterns
- Continuous use: Some protocols use GHRP-6 daily without interruption.
- 5 days on / 2 days off: Commonly reported pattern to reduce potential receptor desensitization.
- Periodic breaks: 4–8 weeks on, 2–4 weeks off. Intended to maintain GHS-R1a sensitivity.
Storage
- Lyophilized powder: Store refrigerated (2–8°C / 36–46°F). Stable for months when kept dry and cold.
- Reconstituted solution: Refrigerate and use within 3–4 weeks. Do not freeze. Discard if solution becomes cloudy or discolored.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What Users Report
The following timeline is compiled from clinician reports, patient surveys, and online communities — not from randomized controlled trials. Individual experiences vary significantly. GHRP-6 has not been evaluated for therapeutic efficacy in Phase 3 human trials.
Reported Timeline
| Timepoint | What Users Typically Report |
|---|---|
| Minutes 20–60 | Intense appetite stimulation — described as a sudden, strong hunger that peaks within 30 minutes and subsides within 60–90 minutes. This is the most immediate and consistent effect reported. |
| Days 1–3 | Appetite pattern becomes predictable. Some users report improved sleep depth and more vivid dreams. Transient flushing or tingling at administration site. |
| Week 1–2 | Consistent sleep improvement. Increased overall food intake. Some users report improved skin appearance and hydration. Subjective sense of enhanced recovery from physical activity. |
| Week 2–4 | Improved exercise recovery and reduced delayed-onset muscle soreness. Water retention may be noticeable (puffy appearance, weight gain). Early body composition trends may emerge. |
| Week 4–8 | Body composition changes become more apparent — though the direction depends on dietary management. Users who manage appetite and maintain caloric control report fat loss and improved muscle tone. Users who do not control increased caloric intake may experience weight gain. |
| Week 8–12+ | Continued body composition effects. IGF-1 elevation plateaus. Some users report appetite stimulation diminishes somewhat with chronic use (possible partial desensitization). |
The Appetite Factor
The appetite stimulation from GHRP-6 is a defining characteristic of the user experience. Reports consistently describe:
- Sudden onset of intense hunger within 20–30 minutes of administration
- Hunger described as "ravenous" or "insatiable" for approximately 30–60 minutes
- Difficulty maintaining caloric restriction during GHRP-6 use
- Some users find the appetite effect beneficial (underweight individuals, athletes in bulking phases)
- Others find it counterproductive for fat-loss goals
Measurable Outcomes
- Serum GH levels: Acute GH peaks confirmed via timed blood draws.
- IGF-1 levels: Sustained elevation (typically 15–40% above baseline) after 2–4 weeks of consistent use.
- Body composition: DEXA scanning can objectively track changes, though dietary management is a major confounding variable due to appetite effects.
Caveats
- Appetite confound: The strong appetite stimulation makes it difficult to separate GH-mediated body composition effects from changes caused by altered caloric intake.
- Individual variability: GH response varies by age, body composition, and baseline hormonal status.
- No controlled efficacy data: User reports have not been validated in placebo-controlled trials for any specific outcome.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Intense appetite stimulation | Very common | Onset within 20–30 minutes. Described as intense, sudden hunger lasting 30–60 minutes. Strongest among GHRP family members (Muccioli et al., 2007). |
| Water retention | Common | GH-mediated sodium and water retention. May manifest as puffy fingers, tight rings, mild ankle swelling, or increased body weight. |
| Cortisol elevation | Common (dose-dependent) | Transient ACTH and cortisol increase. More significant above 200 mcg. Comparable to GHRP-2 (Arvat et al., 2001). |
| Prolactin elevation | Uncommon-common | Mild, transient. Typically not clinically significant at standard doses. |
| Flushing / warmth | Common | Transient warmth or redness, particularly in the face, within minutes of administration. |
| Tingling / paresthesias | Common | Transient tingling sensation, typically in extremities. Self-resolving within minutes. |
| Dizziness | Uncommon | Mild, transient. May relate to vasodilation or blood pressure changes. |
| Injection site reaction | Uncommon | Mild redness, swelling, or tenderness. Resolves within hours. |
| Headache | Uncommon | Mild, self-limiting. More common during initial use. |
| Joint pain / carpal tunnel | Rare | Associated with elevated GH/IGF-1. More likely with higher doses or prolonged use. |
| Gastric discomfort | Uncommon | Some users report stomach cramping or nausea, particularly at higher doses. |
Appetite: Side Effect or Feature?
The appetite stimulation from GHRP-6 warrants special consideration because it is simultaneously the peptide's most reported side effect and its most distinctive pharmacological feature:
- As a side effect: For individuals using GHRP-6 for GH optimization, body composition, or anti-aging, the intense hunger can undermine dietary goals and lead to unintended caloric surplus.
- As a therapeutic feature: For individuals with cachexia, anorexia, or poor appetite due to illness or treatment, the appetite stimulation may be the primary reason for choosing GHRP-6 over other secretagogues.
Theoretical Risks
- GH/IGF-1 and cancer: Elevated GH and IGF-1 levels have been associated with cancer risk in epidemiological studies. Whether intermittent GHRP-6-mediated GH elevation carries comparable risk to sustained elevation is unknown.
- Insulin resistance: GH opposes insulin action. Chronic use could worsen insulin sensitivity in susceptible individuals.
- Chronic cortisol effects: Repeated cortisol stimulation could theoretically contribute to metabolic dysfunction over time, though this has not been studied with chronic GHRP-6 use specifically.
- Receptor desensitization: Chronic GHS-R1a stimulation may reduce receptor sensitivity over time.
- Long-term safety unknown: No controlled long-term human safety data exists.
Drug Interactions
- Glucocorticoids: May blunt GH response and compound cortisol effects.
- Insulin / diabetes medications: GH opposes insulin; monitor blood glucose closely.
- Dopamine agonists: May interact with prolactin effects.
- Somatostatin analogs: Directly antagonize GHRP-6's mechanism.
- Appetite suppressants: Pharmacological conflict with GHRP-6's orexigenic effects.
Contraindications
- Active cancer or recent cancer history — GH/IGF-1 mitogenic properties
- Pregnancy and breastfeeding — no safety data
- Uncontrolled diabetes — GH anti-insulin effects
- Active pituitary tumors — GHS-R1a stimulation
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
Regulatory Status by Jurisdiction
| Jurisdiction | Status | Details |
|---|---|---|
| United States (FDA) | Not approved | No FDA approval for any indication. Not listed on FDA compounding bulk substance categories. Available through research chemical suppliers. |
| European Union (EMA) | Not approved | No EMA marketing authorization. Available through research channels. |
| Japan | Not approved (unlike GHRP-2) | Unlike GHRP-2 (pralmorelin), GHRP-6 does not have diagnostic approval in Japan. |
| WADA | Prohibited | Listed under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Prohibited at all times. |
WADA Prohibition
GHRP-6 is specifically named on the WADA Prohibited List under category S2. It was one of the first peptide secretagogues for which validated detection methods were developed. Urine testing can detect GHRP-6 and its metabolites for a detection window of approximately 4–6 hours after administration, though this window varies by individual and analytical method. Multiple athletes have received anti-doping sanctions related to GHRP-6 use (WADA Prohibited List).
Research Chemical Market
GHRP-6 is widely available through research chemical suppliers worldwide:
- Marketed as "for research purposes only" or "not for human consumption"
- Not manufactured under cGMP pharmaceutical standards
- Quality varies between suppliers; independent analyses show inconsistent purity
- Among the most affordable GH secretagogues in the research chemical market
- Regulatory enforcement is limited, as these products are not directly marketed for human therapeutic use
Legal Status
GHRP-6 is not a scheduled or controlled substance in the United States or most other jurisdictions. It is legal to purchase and possess. However:
- Sale for human therapeutic use without regulatory approval violates FDA regulations
- Use by WADA-governed athletes constitutes a doping violation
- Regulatory status may change as peptide regulation evolves
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Typical Pricing
| Source | Typical Price Range | What You Get | Quality Assurance |
|---|---|---|---|
| Research chemical supplier | $25–$60 per 5mg vial | Lyophilized powder, labeled "for research only." Among the lowest-priced secretagogues. | Variable — some provide COAs; quality varies between suppliers. |
| Peptide specialty vendor | $40–$100 per 5mg vial | Higher-purity lyophilized powder with third-party testing. | Moderate-high — HPLC and mass spectrometry verification. |
| Telehealth / anti-aging clinic | $200–$400/month (all-inclusive) | Provider consultation, prescription, product, and monitoring. | Highest — medical oversight with laboratory monitoring. |
Monthly Cost Estimate
| Protocol | Monthly Peptide Cost | Notes |
|---|---|---|
| 200 mcg 2x daily (research supplier) | $80–$140 | Approximately 12mg/month. 2–3 vials at typical pricing. |
| 200 mcg 2x daily (premium supplier) | $130–$250 | Same usage, higher per-vial cost with quality documentation. |
| Combined GHRP-6 + GHRH analog | $180–$380 | Adding a GHRH analog increases total peptide cost. |
Insurance Coverage
GHRP-6 is not covered by any insurance plan. It has no FDA-approved indication. All costs are out-of-pocket, including the peptide, supplies, consultations, and monitoring bloodwork (though bloodwork may be partially covered under general laboratory benefits).
Additional Costs
- Bacteriostatic water: $5–$15 per vial
- Supplies: $10–$20/month (insulin syringes, alcohol swabs)
- Provider consultation: $100–$300 initial, $50–$150 follow-up
- Blood work: $100–$400 per panel (IGF-1, GH, cortisol, prolactin, metabolic panel)
Cost Comparison
| Treatment | Typical Monthly Cost | Insurance |
|---|---|---|
| GHRP-6 (research) | $100–$250 | Not covered |
| GHRP-2 (research) | $100–$250 | Not covered |
| Ipamorelin (research) | $120–$280 | Not covered |
| Recombinant HGH (pharmaceutical) | $800–$3,000+ | Covered for approved indications |
| Sermorelin (compounded) | $200–$500 | Rarely covered |
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: GHRP-6 is basically HGH.
Answer: GHRP-6 stimulates the body's own pituitary gland to produce and release growth hormone. It does not introduce exogenous GH. The resulting GH elevation follows a pulsatile pattern that mimics natural physiology, unlike exogenous HGH which delivers a non-physiologic bolus. The magnitude of GH elevation from GHRP-6 is also substantially lower than typical therapeutic HGH doses (Bowers, 2001).
Myth: GHRP-6 and GHRP-2 are the same thing.
Answer: While both are hexapeptide GH secretagogues that activate GHS-R1a, they have distinct pharmacological profiles. GHRP-2 is slightly more potent for GH stimulation per microgram. GHRP-6 produces significantly stronger appetite stimulation. Both elevate cortisol and prolactin to similar degrees. They have different amino acid sequences and receptor binding characteristics. The choice between them depends on whether the appetite effect is desired or not (Arvat et al., 2001).
Myth: GHRP-6 is good for fat loss.
Answer: This is complicated. GH has established lipolytic (fat-burning) effects, and GHRP-6 does elevate GH. However, GHRP-6's strong appetite stimulation frequently leads to increased caloric intake, which can offset or reverse any GH-mediated fat loss. For individuals who cannot manage the appetite effect through dietary discipline, GHRP-6 may paradoxically lead to fat gain. Ipamorelin or GHRP-2 (with weaker appetite effects) are generally considered more practical for fat-loss-oriented protocols.
Myth: The hunger from GHRP-6 goes away after a few weeks.
Answer: Some users report a partial reduction in appetite intensity with chronic use, possibly reflecting partial GHS-R1a desensitization. However, the appetite effect generally persists throughout use, though its perceived severity may diminish as users adapt to the pattern. It does not typically disappear entirely (Muccioli et al., 2007).
Myth: GHRP-6 is a steroid.
Answer: GHRP-6 is a synthetic peptide (6 amino acids). It has no structural or functional relationship to anabolic-androgenic steroids. It does not increase testosterone, does not have androgenic effects, and works exclusively through the GH/IGF-1 axis via ghrelin receptor activation (Bowers et al., 1998).
Myth: GHRP-6 is the most dangerous GHRP.
Answer: GHRP-6 has the strongest appetite effect among GHRPs, which is a significant side effect for some users. Its cortisol and prolactin elevation is comparable to GHRP-2. Hexarelin actually produces the most cortisol and prolactin elevation among common GH secretagogues. No GHRP has documented serious safety events in clinical studies, though long-term data is lacking for all of them (Arvat et al., 2001).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- GHRP-6 is a synthetic hexapeptide that stimulates endogenous growth hormone release via ghrelin receptor (GHS-R1a) activation. It was one of the earliest GH secretagogues developed and played a foundational role in ghrelin receptor biology research.
- Its defining characteristic is pronounced appetite stimulation — the strongest among the GHRP family. This is simultaneously a side effect for some users and a potential therapeutic feature for individuals with wasting conditions or poor appetite.
- It has Phase 1–2 human data demonstrating reliable GH stimulation. It is not approved for therapeutic use by any major regulatory authority, unlike GHRP-2 which has diagnostic approval in Japan.
- GHRP-6 elevates cortisol and prolactin at higher doses, similar to GHRP-2 and in contrast to the more selective Ipamorelin.
- Preclinical cardioprotection data is notable, with robust evidence for reduced myocardial infarct size and improved cardiac function in animal models — though this has not been validated in human trials.
- Cost ranges from $100–$250/month through research chemical suppliers, making it among the most affordable GH secretagogues. Insurance does not cover it.
- WADA prohibits GHRP-6 under category S2. Detection methods are established.
Who Might Consider GHRP-6
Based on the available evidence and clinical practice patterns, GHRP-6 may be worth discussing with a healthcare provider for individuals who:
- Want to stimulate endogenous GH production and specifically benefit from appetite stimulation (e.g., underweight individuals, those with poor appetite, athletes in caloric surplus phases)
- Have cachexia or illness-related wasting and need both GH elevation and appetite support
- Have access to a knowledgeable provider who can monitor hormonal parameters (GH, IGF-1, cortisol, prolactin)
- Understand the appetite implications and have a dietary management plan
- Are willing to undergo baseline and follow-up blood work
- Accept the experimental nature of the evidence base
Who Should Consider Alternatives
- Individuals prioritizing fat loss: Ipamorelin or GHRP-2 produce less appetite interference
- Those wanting minimal hormonal side effects: Ipamorelin offers the most selective GH stimulation with minimal cortisol/prolactin effects
- Competitive athletes: GHRP-6 is WADA prohibited
Questions to Ask a Provider
- Given my goals, is GHRP-6's appetite effect beneficial or counterproductive?
- Would a more selective secretagogue (Ipamorelin) or a more potent one (GHRP-2) serve my purposes?
- What dose will minimize cortisol and prolactin effects while maintaining GH stimulation?
- Should I combine GHRP-6 with a GHRH analog?
- What baseline and monitoring blood work is appropriate?
- How will I manage the appetite stimulation relative to my dietary goals?
- Where will the GHRP-6 be sourced, and what quality verification exists?
- What is the recommended duration and cycling pattern?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
Comprehensive Reviews & Pharmacology
- Bowers et al. (1998) — "Unnatural growth hormone-releasing peptide begets natural ghrelin" — Journal of Clinical Endocrinology & Metabolism
- Bowers (2001) — "Selective growth hormone secretagogues" — Hormone Research
- Muccioli et al. (2007) — "Neuroendocrine and peripheral activities of ghrelin" — Frontiers in Neuroendocrinology
Human Clinical Studies
Cardioprotection
- Muccioli et al. (2007) — "Cardiac GHS-R1a expression and cardioprotective effects" — Endocrine Reviews
- Berlanga et al. (2007) — "GHRP-6 in wound healing and tissue repair" — Growth Hormone & IGF Research
Wound Healing
Appetite & Metabolism
- Muccioli et al. (2007) — Appetite regulation via ghrelin receptor
- Arvat et al. (2001) — Appetite stimulation in humans
Mechanism of Action
- Bowers et al. (1998) — GHS-R1a receptor activation and GH release
- Bowers (2001) — GHRH synergy and pulsatile secretion
Regulatory & Classification
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
